Baiji Hongye (Nantong) Pharmaceutical Technology Co., Ltd.

Primary objectives: 1) To evaluate the safety and tolerability of picolipid acetate injection in patients with relapsed/refractory leukemia; 2) To assess the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of picolipid acetate injection; 3) To determine the Phase II dosing regimen. Secondary objectives: 1) To evaluate the pharmacokinetic (PK) properties of picolipid acetate injection in patients with relapsed/refractory leukemia; 2) To evaluate the preliminary efficacy of picolipid acetate injection in patients with relapsed/refractory leukemia.

Primary objectives: 1) To evaluate the safety and tolerability of SS-001 in patients with B-cell lymphoma. 2) To evaluate the maximum tolerated dose (MTD) and recommended dose (RP2D) of SS-001 for Phase II clinical trials. Secondary objectives: 1) To evaluate the human pharmacokinetic (PK) characteristics of single and multiple oral SS-001 in patients with B-cell lymphoma. 2) To evaluate the BTK target occupancy of SS-001 in peripheral blood mononuclear cells (PBMCs). 3) To preliminarily evaluate the efficacy of SS-001 in patients with B-cell lymphoma.